Freytag Svend O, Stricker Hans, Movsas Benjamin, Kim Jae Ho
Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA.
Mol Ther. 2007 Jun;15(6):1042-52. doi: 10.1038/sj.mt.6300162. Epub 2007 Apr 3.
Despite recent advances in early detection and treatment, prostate cancer is still the second leading cause of cancer death in men in the United States, and approximately 27,000 men will die from it this year. Better treatments are needed for aggressive forms of localized disease and hormone-refractory metastatic disease. Recently, several gene therapy strategies have generated provocative results in early-stage clinical trials, raising the possibility that gene therapy may have the potential to affect both localized and metastatic disease. Much work lies ahead. Nevertheless, for the time being, these studies provide hope that gene therapy may someday earn a place in the management of prostate cancer.
尽管在早期检测和治疗方面取得了最新进展，但前列腺癌仍是美国男性癌症死亡的第二大主要原因，今年约有27000名男性将死于该病。对于侵袭性局部疾病和激素难治性转移性疾病，需要更好的治疗方法。最近，几种基因治疗策略在早期临床试验中产生了令人振奋的结果，这增加了基因治疗可能对局部和转移性疾病都有潜在影响的可能性。未来还有很多工作要做。然而，目前这些研究提供了希望，即基因治疗有朝一日可能在前列腺癌的治疗中占有一席之地。
